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Abstract
Two of the greatest challenges in regenerative medicine today remain (1) the ability to culture human embryonic stem cells
(hESCs) at a scale sufficient to satisfy clinical demand and (2) the ability to eliminate teratoma-forming cells from
preparations of cells with clinically desirable phenotypes. Understanding the pathways governing apoptosis in hESCs may
provide a means to address these issues. Limiting apoptosis could aid scaling efforts, whereas triggering selective apoptosis
in hESCs could eliminate unwanted teratoma-forming cells. We focus here on the BCL-2 family of proteins, which regulate
mitochondrial-dependent apoptosis. We used quantitative PCR to compare the steady-state expression profile of all human
BCL-2 family members in hESCs with that of human primary cells from various origins and two cancer lines. Our findings
indicate that hESCs express elevated levels of the pro-apoptotic BH3-only BCL-2 family members NOXA, BIK, BIM, BMF and
PUMA when compared with differentiated cells and cancer cells. However, compensatory expression of pro-survival BCL-2
family members in hESCs was not observed, suggesting a possible explanation for the elevated rates of apoptosis observed
in proliferating hESC cultures, as well as a mechanism that could be exploited to limit hESC-derived neoplasms.
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Introduction
Apoptosis is a sophisticated mechanism for eliminating
unwanted cells. The signaling pathways that regulate apoptosis
vary among different cell types [1,2], suggesting that apoptotic
regulatory pathways are determined by differentiation status,
wherein one cell lineage responds to apoptotic cues differently
than others. Little is currently known about how the common
precursor from which all tissues are derived - human embryonic
stem cells (hESCs) - regulate entry into apoptosis. The importance
of understanding these pathways is highlighted by one of the most
significant obstacles to regenerative medicine: Transplantation of
desired cell types contaminated with pluripotent cells can result in
the formation of teratomas - tumors, usually benign, harboring
differentiated cells of all lineages. If the primary pathways that
govern apoptosis were to be determined in hESCs, strategies could
be devised to exploit these pathways to eliminate potential
teratoma-forming cells. Additionally, since large-scale expansion
of hESCs remains a challenge, optimization of growth conditions
could be achieved through reducing levels of apoptosis.
The most common apoptotic pathways are intrinsic pathways
mediated via the mitochondrion [3,4]. Varied cell death triggers
cause mitochondrial outer-membrane permeabilization (MOMP),
prompting release of cytochrome c from the mitochondrial inter-
membranous space. Cytochrome c then activates caspases that
effect destruction of the cell [3,4]. MOMP is controlled by the
BCL-2 protein family, which includes both pro-apoptotic (BAX
and BAK) and pro-survival family members (BCL-2, BCL-xL,
BCL-w, A1, and MCL-1), as well as the BCL-2 homology domain
3 (BH3)-only family members (BID, BAD, BIM, BIK, BLK,
PUMA, NOXA, BNIP3, and HRK) [5]. The ultimate determi-
nant of cell survival or apoptosis is the balance of active pro-
survival BCL-2 family members and pro-apoptotic BCL-2 family
members [5]. Not all BCL-2 family members are expressed in
every cell type, and different triggers of apoptosis both activate
specific pro-apoptotic BCL-2 family members and inactivate
specific pro-survival BCL-2 family members [6,7].
Considering their central importance in regulating apoptosis,
determining the relative expression levels of the pro-apoptotic and
pro-survival members of the BCL-2 family is an essential first step
in describing apoptotic pathways in hESCs. In the current studies,
we have addressed the following questions: (1) What is the
expression of the compendium of BCL-2 family members in
hESCs? (2) How does this gene expression profile compare to that
in differentiated cell types? We compared the BCL-2 family
member gene expression profile in pluripotent hESC lines TE06
and BG01 with those in hESC-derived neural stem cells, seven
human primary cell lines from various origins, and two cancer cell
lines (Table 1). The gene expression of five pro-survival BCL-2
family members, eight BH3-only BCL-2 family members, as well
as BAX and BAK, was determined by quantitative reverse
transcriptase polymerase chain reaction (qPCR).
We found that, compared to differentiated cells, proliferating
hESCs express significantly higher levels of pro-apoptotic BCL-2
family members, including NOXA, BIK, BIM, BMF, and PUMA.
Furthermore, elevated levels of these pro-apoptotic transcripts
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28530were not countered by elevated levels of pro-survival BCL-2 family
members in hESCs. The results of this study suggest that hESCs
might utilize unique mechanisms to regulate programmed cell
death - mechanisms that could either be minimized to make large-
scale production of hESCs more feasible or exploited to minimize
the risk of teratoma formation upon transplantation of hESC-
derived cell types.
Results
In order to determine which BCL2 family members are
expressed in pluripotent human embryonic stem cells, we
compared the expression profile of BCL-2 family members
between hESCs and differentiated cells (see Table 1) by qPCR.
Selection of housekeeping genes
Because we chose to study gene expression in a collection of cells
of seemingly disparate phenotypes, it was important to determine
carefully the most appropriate reference gene(s) for normalization
of the qPCR expression data. We followed the method described
by Vandesompele et al. [8], which allows systematic evaluation of
a collection of reference genes for those that vary least across the
cell lines being analyzed. In this method, the normalization factor
is a calculated value determined by the geometric mean of the
expression levels of the best-performing reference genes (see
methods, and REF [8]).
We selected a total of 15 genes for the purpose of normalizing
qPCR data based their frequent use to normalize expression data
(B2M, UBC, TBP, ACTB, YWHAZ, SDHA, RPL13A, GAPDH,
HPRT1) or based on their identification as the least variant
mRNAs among a large collection of gene expression data (ATP5J,
SPR14, GUSB, OAZ1, PGK1, PPIA [9]). The expression stability
among the set of cells outlined above, M (see materials and
methods for details), was calculated for each gene from our data
set. From this analysis, the least stable control genes were
eliminated, and new values for M could be calculated from the
remaining list of genes. The best-performing pair of genes, PGK1
and PPIA, was identified after step-wise exclusion of the least
stable gene (highest value of M) in each of 13 iterative rounds of
expression stability calculations (Figure 1).
Expression of lineage-specific markers
Once the optimum pair of reference genes was identified, we
assayed the abundance of lineage-specific markers by qPCR.
Expression of the transcription factors NANOG and SOX2 was
Table 1. Cells used in this study.
Abbreviation Cell Line Description Source
TE06 (MEF) hESC line TE06 co-cultured with MEFs Xianmin Zeng
1
TE06 (MAT) hESC line TE06 grown on Matrigel in MEF-conditioned medium Xianmin Zeng
1
BG01 (MEF) hESC line BG01 co-cultured with MEFs NSCB
2
BG01 (MAT) hESC line BG01 grown on Matrigel in MEF-conditioned medium NSCB
2
TE06-NSCs TE06-derived neural stem cells (NSCs) This study
HDF Dermal fibroblasts
3 Invitrogen
HEK Epidermal keratinocytes
3 Invitrogen
HEMNn-LP Epidermal melanocytes, neonatal, low pigmentation
3 Invitrogen
HMVEC Microvascular endothelial cells
3 Invitrogen
HUVEC Umbilical vein endothelial cells
3 Invitrogen
HPASMC Pulmonary artery smooth muscle cells
3 Invitrogen
HMEC Mammary epithelial cells
3 Invitrogen
MCF-7 Human cancer cell line MCF-7 ATCC
HeLa Human cervix Aden carcinoma cell line ATCC
1Buck Institute for Research on Aging, Novato, CA.
2National Stem Cell Bank, WiCell Research Institute, Madison, WI.
3Human primary cells.
doi:10.1371/journal.pone.0028530.t001
Figure 1. Selection of optimal reference genes: PGK1 and PPIA.
15 genes were evaluated for their appropriateness for use as reference
genes to normalize all subsequent data. Using a method described by
Vandesompele et al. [8] genes were ranked by a stability coefficient M
and those genes having the lowest stability (greatest value of M) were
eliminated from the subsequent round of stability calculations. The
gene eliminated from each round is indicated in parentheses.
doi:10.1371/journal.pone.0028530.g001
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cells with MEFs or on Matrigel in the presence of MEF-
conditioned medium yielded similar expression (Figure 2). Addi-
tionally, the BG01 and TE06 cells also expressed pluripotency
marker proteins E-cadherin, Oct-3/4, CD9, NANOG, and
PODXL (Figure 3), as well as SOX2 (data not shown). SOX2
transcript was also elevated in TE06-derived neural stem cells
(TE06-NSCs), consistent with the transcription profile of NSCs
[10,11].
We also tested the expression status of genes normally active in
differentiated cells. Elevated transcript levels of MAP2, a neuronal
marker, was seen only in TE06-NSCs (Figure 2). We also found
that GATA-6, a transcription factor expressed in endoderm and
some mesoderm-derived tissues, was predominantly expressed in
pulmonary artery smooth muscle cells (Figure 2, [12]), but was also
expressed in umbilical vein endothelial cells, consistent with what
has been observed previously [13,14]. Some GATA-6 expression
could also be seen in the cancer lines MCF-7 and HeLa.
The immediate goal of this study was to characterize BCL-2
family members in hESCs, and determine whether their
expression was either unique or absent in pluripotent human
embryonic stem cells. The method we chose to identify such BCL-
2 members from the qPCR data was to calculate a ratio of the
average BCL-2 family member expression in hESCs to the
expression among the non-hES cell types. The median was used
for the non-hES cell types because in many instances expression
was particularly high, or low, in only one or two cell types. A
simple ranking of the ratios for each BCL-2 family member
revealed a surprising finding: The top five ranking BCL-2 family
members having the greatest ratio of hESC:non-hESC expression
were all pro-apoptotic BH3-only BCL-2 family members (Table 2).
Two of the pro-apoptotic BCL-2 family members were expressed
with a greater than 10-fold increase in hESCs versus non-hESCs:
NOXA was expressed at an hESC:non-hESC ratio of 50, and BIK
was expressed at an hESC:non-hESC ratio of 25 (Table 2).
NOXA, BIK, BIM, and BMF were expressed in hESCs at levels
that were significantly higher than those of the non-hES cell types
(Figure 4, p,0.001, 2-tailed student’s t test, for most pair-wise
comparisons between non-hES cell type and average hESC
expression). Not every pro-apoptotic BCL-2 family member
transcript was elevated in hESCs versus non-hES cell types,
however: The pro-apoptotic BH3-only family member BNIP3 was
ranked second only to the pro-survival BCL-2 family member A1
in the non-hESC:hESC expression ratio (Table 2 and Figure 5).
We expected to find instances wherein anti-apoptotic BCL-2
family members would be elevated in hESCs relative to the other
cell types, so as to counter the hESC-restricted activity of the pro-
apoptotic BH3-only BCL-2 family members NOXA, BIK, BIM,
BMF, and PUMA. However, none of the five pro-survival BCL-2
Figure 2. Cell lines express appropriate markers of pluripotency and lineage. Abundance of gene transcripts were determined by qPCR,
and is expressed in linear arbitrary units. A. Expression of NANOG, a marker of pluripotency. B. Expression of SOX2, a marker of pluripotency and
neural precursor cells. C. Expression of the microtubule-associated protein MAP2, a marker of neural cells. D. Expression of the transcription factor
GATA6, a marker of heart and endoderm-derived tissues.
doi:10.1371/journal.pone.0028530.g002
Figure 3. hESC lines BG01 and TE06 express protein markers of
pluripotency. Antibodies against protein markers of pluripotency
were used to label hESCs via immunofluorescence. Fixed TE06 (A, C, E)
or BG01 (B, D, F) cells were incubated with primary antibodies directed
against CD9 (A, B), Oct4 (A, B, E, F), E-cadherin (C, D), Nanog (C, D), or
PODXL (E, F) followed by incubation with Alexa fluor 488 or 555
conjugated secondary antibodies. Pictures are 1006wide-field images
captured on an inverted fluorescence microscope.
doi:10.1371/journal.pone.0028530.g003
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sion to the extent that NOXA, BIK, BMF, and PUMA did. Pro-
survival BCL-2 family members were found to have either greater
expression in non-hES cell types than hESCs (A1 and BCL-w) or
statistically insignificant differences between hESCs and non-
hESCs (BCL-x and MCL-1). The one exception was the canonical
anti-apoptotic molecule, BCL-2, whose average expression in
hESCs was about 4-fold greater than the median non-hESC
expression.
As an independent means of identifying BCL-2 family members
that are uniquely expressed in either hESCs or non-hESCs, we
used a clustering alignment algorithm to group the genes based on
expression profiles. We included in our clustering analysis genes
that are markers of pluripotency (SOX2 and NANOG) as well as
markers of differentiated cells (MAP2 and GATA6). We also
included the tumor suppressor p53 in our clustering analysis based
on our finding that of the top five ranked genes having the greatest
hESC-specific expression pattern (Table 2), three of these are
direct targets of p53 transactivation activity: NOXA [15], BIK
[16], and PUMA [17,18]. BAX, another known target of p53 [19],
demonstrated slightly less hESC-specific expression, ranking
seventh on a list of all genes from this study. Furthermore, recent
evidence suggests that BIM is an indirect target or p53 [20].
We found that p53-regulated pro-apoptotic BCL-2 family
members were clustered into two groups having very similar
expression profiles: One group included p53 itself, along with the
pluripotency marker SOX2 and the pro-apoptotic BCL-2 family
members PUMA and BAX (Figure 6, correlation coefficient 0.75).
The other group consisted of the pluripotency marker NANOG as
well as the pro-apoptotic BCL-2 family members BIK, NOXA,
and BIM (Figure 6, correlation coefficient 0.65). Although other
smaller clusters of gene expression profiles were observed, none
were correlated to the same degree as those seen clustered with
SOX2 and NANOG. These results, taken together with the BCL-
2 comparison data, suggested that high basal transcript expression
of potent pro-apoptotic BCL-2 family members PUMA, NOXA,
BIM, BIK, and BAX, is a genuine general feature of pluripotent
human embryonic stem cells.
Discussion
In this study we show that, when compared to differentiated
cells or cancer cells, hESCs express elevated levels of multiple pro-
apoptotic BCL-2 family members. We took advantage of a
microfluidics-based qPCR platform to measure all of the human
BCL-2 family members across 48 samples simultaneously. The
samples consisted of 12 cell lines each having 3 or, in some cases, 4
replicate cultures, which were established from separately thawed
cryologically-preserved cell stocks. Additionally, hESC lines (BG01
and TE06) were each grown under both MEF feeder and feeder-
free conditions. Owing to the disparate cell types evaluated for
gene expression, we first measured expression levels of 15
reference genes, and identified two genes (PGK1/PPIA) that best
reflected total mRNA levels. As a result of this experimental
design, we are confident that the gene expression levels calculated
from our qPCR experiments accurately reflect differences in
abundance of mRNA transcripts among the dozen cell types
studied. We hypothesized that one, or perhaps two BH3-only
BCL-2 family members would be dominantly expressed in hESCs,
and that these pro-apoptotic transcripts would be balanced by
select pro-survival BCL-2 family members. From these patterns of
expression, we hypothesized that the principal pathways governing
apoptosis in hESCs could be revealed.
Contrary to our expectations, we found that hESCs express the
pro-apoptotic BH3-only BCL-2 family members NOXA, BIK,
BIM, BMF, and PUMA at levels far greater than that seen in the
seven human primary cells, hESC-derived neural stem cells, or
cancer lines (Figure 4). However, only one of the pro-survival
BCL-2 family members, BCL-2, was found to be moderately
elevated in hESCs compared to that seen in other cell types.
Transcript abundance of two other pro-survival BCL-2 family
members, BCL-x and MCL-1, was merely comparable to that
seen in the other ten cell lines, and expression levels of BCL-w,
and A1 were minimal in hESCs (our assays did not distinguish
between transcripts for BCL-xL and BCL-xS). What is more,
unsupervised hierarchical clustering of these gene expression
profiles resulted in the clustering of NOXA, BIK, BIM, BMF, and
PUMA together with hESC pluripotency markers like NANOG
and SOX2. We interpreted these findings as further indication
that elevated expression of these BH3-only BCL-2 family members
is a genuine feature of hESCs when they are either co-cultured
with MEFs or grown on Matrigel with conditioned media.
Despite the fact that well over a decade has passed since the first
human embryonic stem cell lines were established, we have yet to
uncover the complete list of MEF-derived molecular determinants
of hESC pluripotency and proliferation [21,22]. It is formally
possible that a deficient trophic environment explains the
ubiquitous observation that hESCs have elevated rates of apoptosis
[23–25]. From this, it would logically follow that death of hESCs
in culture might require certain pro-apoptotic BH3-only BCL-2
family members. However, it was only recently reported that
BCL-2 family members play a role in governing basal rates of
apoptosis in hESCs [23,26]. In one study by Ardehali et al., BCL-2
overexpression in hESCs was found to improve overall growth
rates, eliminate reliance on knock-out serum replacement, increase
clonogenicity after single cell dissociation, and reduce apoptosis
associated with newly formed embryoid bodies [26]. In another
study by Ohgushi et al., apoptosis in hESCs resulting from single
cell dissociation was shown to be inhibited by overexpression of
the pro-survival BCL-2 family member BCL-xL [23]. That a pro-
survival BCL-2 family member could reduce dissociation-induced
apoptosis and increase the overall growth rate of hESCs suggests
that basal rates of apoptosis are most likely mediated by
constitutive expression of pro-apoptotic BH3-only family mem-
bers. Our data suggest that the pro-apoptotic BH3-only family
members responsible for basal rates of apoptosis include NOXA,
BIK, BIM, BMF, and PUMA, or a subset thereof.
Table 2. BCL-2 family members with hESC or non-hESC
expression bias.
hESC
1:Non-hESC
2 Non-hESC
2:hESC
1
Rank Gene Ratio Gene Ratio
1 NOXA 50.1 A1 102
2 BIK 25.8 BNIP3 3.3
3B I M
3 8.1 BCL-w 3.1
4 BMF 8.0 BAD 1.9
5 PUMA 7.4 BID 1.2
6B I M
4 4.7
7 BCL2 3.7
1Mean expression of all hESC samples.
2Median of non-hESC expression values.
3qPCR assay covers all three BIM transcript variants: BIM-L, BIM-EL, and BIM-S.
4Different primer/ probe set that also detects all three BIM transcripts.
doi:10.1371/journal.pone.0028530.t002
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BCL-2 family members NOXA, BIK, BIM, BMF and PUMA in
hESCs, it is conceivable that the activities of these molecules would
be inhibited via post-translational modifications, and that
apoptosis in hESCs may be controlled by other novel signaling
pathways. Accumulating evidence in the literature indicates that
many BH3-only BCL-2 family members are regulated by post-
translational modifications [5]. Whereas nothing is currently
known about what, if any, post-translational modifications of
pro-apoptotic BH3-only BCL-2 family members might occur in
hESCs, limiting the apoptotic activity of these molecules to some
extent would be essential for net proliferation to occur.
For many of the pro-apoptotic BCL-2 family members,
including BAD, BIM, BMF, BIK and NOXA, apoptosis-
promoting activity can be regulated by phosphorylation. Perhaps
the most well known example of this is in the case of BAD, wherein
phosphorlyation of serine residues by multiple kinases, including
AKT, can promote complex formation with 14-3-3, resulting in
cytosolic sequestration [5,27–39]. Similarly, ERK1/2 or RSK1/2-
mediated phosphorylation of BIM blunts the pro-apoptotic activity
of this molecule [5,40,41]. Instead of being sequestered in the
cytosol by 14-3-3, as in the case of BAD, BMF associates with
DLC2, thereby limiting BMF’s pro-apoptotic activity [5,42]. BIK
is also under post-translational control, but in this case, casein
kinase-mediated phosphorylation of BIK stimulates its apoptotic
function [5,43,44]. More recently, NOXA was also discovered to
be the target of phosphorylation [45]. The atypical cyclin-
dependent kinase CDK5 phosphorylates NOXA when cells
experience glucose replete conditions. Phosphorylation of NOXA
causes cytosolic sequestration via an unknown mechanism and
blunted apoptotic function, in addition to inducing a novel
NOXA-mediated stimulation of the pentose phosphate pathway
[45]. To date, no evidence of post-translational modifications of
PUMA have been identified, but based on the growing list of post-
translational modifications that regulate BCL-2 family member
function, post-translational modifications of PUMA remain a
distinct possibility.
The picture that emerges is one in which hESCs may express
pro-apoptotic BH3-only BCL-2 family members in a constitutive
fashion, but that the apoptotic function of these molecules could be
held in check either by complex formation with pro-survival BCL-
2 family members (likely BCL-xL or MCL-1) or by apoptotic-
inhibitory phosphorylation of NOXA, BIK, BIM, BMF and
possibly PUMA, or complex formation with other inhibitory
molecules (e.g., 14-3-3 for BAD, DLC2 for BMF). The advantage
of such a scenario might be that apoptotic responses could be
engaged more rapidly and robustly, requiring only kinase cascades
to control activation of apoptosis. The danger to the cell, and a
possible explanation of the challenge of growing hESCs, is that
seemingly minor changes in the environment could potentially
result in cell death.
In conclusion, we have shown that, compared with differenti-
ated cells, hESCs express an unusual repertoire of BCL-2 family
members. hESCs cultured under standard growth conditions
contain elevated levels of transcripts encoding pro-apoptotic BH3-
only BCL-2 family members NOXA, BIK, BIM, BMF, and
Figure 4. A cohort of pro-apoptotic BH3-only BCL-2 family
members are expressed primarily in hESCs. Abundance of gene
transcripts were determined by qPCR, and is expressed in arbitrary
units. A. NOXA, B. BIK, C. BIM (assay detected all three transcript
variants: BIM-L, BIM-EL, and BIM-S), D. BMF, E. PUMA, F. BNIP3. Asterisks
indicate values that differ significantly from the average hESC
expression level (p,0.001, two-tailed student’s t test).
doi:10.1371/journal.pone.0028530.g004
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fact that complementary increases in pro-survival BCL-2 family
members are not seen in hESCs, suggests that this expression
profile could help to explain the elevated rates of apoptosis seen in
hESCs. Recent reports demonstrating that overexpression of BCL-
2 [26] or BCL-xL [23] limits dissociation-induced apoptosis and
increases overall growth rates is compatible with our finding that
hESCs express elevated levels of pro-apoptotic BH3-only BCL-2
family members, and thus may be ‘‘primed’’ for apoptosis in a way
Figure 6. Hierarchical cluster analysis of BCL-2 family members
in hESCs and non-hESCs. qPCR data was clustered via a two-way
unsupervised clustering algorithm (Cluster 3.0) and visualized as a heat
map (Java TreeView 1.1). Parallel cultures of each cell line (number):
TE06-NSCs (4), TE06 MAT (4), TE06 MEF (4), BG01 MEF (4), BG01 MAT (4),
HEMn-LP (3), HEK (3), HMVEC (2), HDF (3), HUVEC (3), HPASMC (3), HMEC
(3), MCF-7 (3), and HeLa (3). For many genes, assays detected all or a
subset of the transcript variants.
1Variants 1–7.
2Variants alpha, beta,
delta, and sigma.
3Variants alpha and delta.
4Varient sigma.
5BIM-L, BIM-
EL, and BIM-S.
6BIM-L, BIM-S.
7BIM-S.
8Variant 5
9Variant alpha.
10Variants
alpha and beta.
11Variant 1.
12Variant 2.
13BCL-xL and BCL-xS.
14Variant
3.
15Variants 1 and 2.
doi:10.1371/journal.pone.0028530.g006
Figure 5. Expression of pro-survival BCL-2 family members.
Abundance of gene transcripts were determined by qPCR, and is
expressed in linear arbitrary units. A. BCL-2, B. BCL-w, C. BCL-x (assay
detected both transcript variants: BCL-xS and BCL-xL), D. A1, E. MCL-1.
Asterisks indicate values that differ significantly from the average hESC
expression level (p,0.001, two-tailed student’s t test).
doi:10.1371/journal.pone.0028530.g005
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improvements in hESC culture methods could reduce the basal
rates of apoptosis. With the large-scale propagation of hESCs
remaining a major hurdle to the development of hESC-based
therapies, our ability to limit the basal rate of apoptosis will be an
important step toward achieving this goal.
Furthermore, given that, even in the face of elevated expression
of pro-apoptotic BH3-only BCL-2 family members, hESCs are
able to proliferate under standard growth conditions, hESCs might
utilize novel regulatory mechanisms to control initiation of
apoptosis. The importance of such a possibility is highlighted by
the fact that one of the greatest obstacles to overcome in
regenerative medicine is the potential of introducing teratoma-
forming cells during transplantation of cells with desired
phenotypes. Therefore, our ability to exploit apoptotic pathways
unique to hESCs could improve the clinical outcome of therapies
relying on hESC-derived cells.
Materials and Methods
Ethics statement
All protocols involving hESCs were approved by the UC Davis
Stem Cell Oversight Committee. The two human embryonic stem
cell lines used in this study were TE06 and BG01. TE06 cells were
received from the laboratory of Xianmin Zeng, Buck Institute for
Research on Aging, Novato, CA. BG01 cells were purchased from
the National Stem Cell Bank, WiCell Research Institute, Madison,
WI.
Growth of non-hESCs
HeLa cervical carcinoma cells and MCF-7 breast carcinoma
cells were purchased from the American Type Culture Collection
(ATCC, Manassas, VA), and were cultured in DMEM, 2 mM L-
glutamine, 50 units/ml penicillin G, 50 ug/ml streptomycin
sulfate (Life Technologies, Carlsbad, CA) and 10% FBS (Sigma,
St. Louis, MO). The seven human primary cell lines used in this
study were purchased and grown exactly as recommended by the
manufacturer using specialty media all supplied by the manufac-
turer (Life Technologies). Human umbilical vein endothelial cells
(HUVEC, Life Technologies) were grown in LSGS-supplemented
Medium 200. Human epidermal melanocytes-neonatal lightly
pigmented cells (HEMn-LP, Life Technologies) were grown in
HMGS-supplemented Medium 254. Human mammary micro-
vasculature endothelial cells, neonatal dermis (HMVECnd, Life
Technologies) were grown in MVGS-supplemented Medium 131.
Human pulmonary artery smooth muscle cells (HPASMC, Life
Technologies) were grown in SMGS-supplemented Medium 231.
Human epidermal keratinocytes, neonatal (HEKn, Life Technol-
ogies) were grown in HKGS-supplemented Epilife media. Human
dermal fibroblasts, neonatal (HDFn, Life Technologies) were
grown in LSGS-supplemented Medium 106. Human mammary
epithelial cells (HMEC, Life Technologies) were grown in
HuMEC- and bovine pituitary extract-supplemented HuMEC
Basal Serum Free Medium.
Growth of hESCs on Mouse Embryonic Fibroblasts
hESC lines BG01 and TE06 were propagated on mitomycin-C-
inactivated MEFs (Millipore, Billerica, MA) in hESC medium:
DMEM/F12 (1:1) with 20% knockout serum replacement, 2 mM
nonessential amino acids, 2 mM L-glutamine, 50 units/ml
penicillin G, 50 ug/ml streptomycin sulfate (all from Life
Technologies), 0.1 mM beta-mercaptoethanol (Millipore, Bill-
erica, MA), and 4 ng/ml bFGF (PreproTech, Rocky Hill, NJ).
hESCs were passaged enzymatically every 7 days. Briefly, cells
were washed with DMEM/F12 (1:1), then incubated with
collagenase IV (1 mg/ml in DMEM/F12, Life Technologies) for
40 minutes at 37uC and 5% CO2. Any semi-adhered hESC
colonies were pushed off the plate with a plastic pipette, and
colonies were sedimented via centrifugation. Cell colonies were
broken up into smaller cell aggregates by trituration of the
harvested colonies in hESC medium. Triturated cells were then
plated on new mitomycin-C-inactivated MEFs and incubated at
37uC with 5% CO2 for 48 h, and media was changed daily.
Growth of hESCs without feeders
MEF conditioned medium (CM) was prepared by culturing
mitomycin-C-inactivated MEFs in hESC medium. After 24 h of
incubation, the medium was collected and stored at 4uC. The
conditioned medium collected for six consecutive days from the
same MEF culture was pooled, filtered through a 0.2 um
membrane (Nalgene, Rochester, NY), and aliquots were stored
at 220uC. Before use, thawed CM aliquots were supplemented
with an additional 4 ng/ml bFGF. hESCs were harvested using
collagenase as described above, with the exception that colonies
were triturated in CM. The dissociated hESCs were seeded on
Matrigel-coated plates (1:50 dilution, BD, Franklin Lakes, NJ) in
CM, and media was changed daily with CM until the hESCs
reached approximately 65% confluency. Cells were passaged
every 7 days.
Immunocytochemistry
Immunostaining was performed as described in Madden et al.
[46]. Briefly, hESCs were co-cultured with MEFs on glass
coverslips coated with gelatin. Cells were fixed in 4% PFA for
10 min, permeabilized in 0.05% saponin for 5 min, and incubated
in ice-cold acetone for 15 min. Primary antibodies (all from R&D
Systems, Minneapolis, MN) were diluted with 1% wt/v BSA
(Sigma) in PBS (PBA), and incubated with cells for 1.5 h at room
temperature; anti-NANOG (R&D Systems cat no. AF1997,
1:100), anti-PODXL (cat no. MAB1658, 1:100), anti-SOX2 (cat
no. MAB2018, 1:100), anti-OCT3/4 (cat no. AF1759, 1:100),
anti-CD9 (cat no. MAB1880, 1:100), and anti-E-Cadherin (cat
no. MAB1838, 1:10). Anti-mouse or anti-rabbit secondary anti-
bodies conjugated to either Alexa Fluor 488 or Alexa Fluor 555
(Life Technologies) were diluted 1:200 in PBA and incubated for
1.5 h at room temperature in the dark. Washed cells were then
post-fixed with 2 ug/ml Hoechst 33342 (Life Technologies) in 4%
PFA for 10 min and mounted on to glass slides with SlowFade
antifade reagent following the manufacturer’s instructions (Life
Technologies). Fluorescence images were viewed with Nikon
fluorescence objectives using a Nikon TE300 (Nikon Inc., Melville,
NY). Images were captured with a Photometrics CoolSNAP EZ
digital camera (Roper Scientific, Inc., Germany) using Simple PCI
software (Compix Inc. Imaging Systems, Cranberry Township,
PA). The brightness, contrast, and unsharp mask functions of
Adobe Photoshop CS were used to optimize the images (Adobe
Systems Inc., San Jose California).
Karyotypic analysis
Karyotypic analysis of our expanded banks of hESCs (BG01
and TE06) was performed by Cell Line Genetics (Madison, WI).
See Figure S1.
RNA Isolation
For the purposes of this study, cultures were established from
liquid nitrogen storage from three or, in some cases, four vials of a
previously expanded cell line. Replicate cultures were maintained
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grown. Independently established cultures were never mixed or
combined with other cultures of the same line.
RNA was isolated from cells grown in parallel cultures (replicate
n): BG01 on MEFs (4), BG01 on Matrigel (4), TE06 on MEFs (4),
TE06 on Matrigel (4), TE06-derived NSCs (4), human pulmonary
smooth muscle cells (3), human mammary epithelial cells (3),
human epidermal keratinocytes (3), human epidermal fibroblasts
(3), human umbilical vein endothelial cells (3), human microvas-
cular endothelial cells (3), human epidermal melanocytes (3), the
cancer lines HeLa (3) and MCF7 (3). RNA was also isolated from
mouse embryonic fibroblasts to verify that qPCR primer-assay
pairs were human-specific.
hESC colonies were harvested in a similar fashion used for
routine passaging with the exception that cells were treated with
collagenase for 20 min only. Colonies were collected by
centrifugation (2006g) for 2 min, the supernatant was aspirated,
cells were frozen in a bath of dry-ice/ ethanol, and transferred to a
280uC cryo-freezer for storage. The seven primary cell lines
(human pulmonary smooth muscle cells, human mammary
epithelial cells, human epidermal keratinocytes, human epidermal
fibroblasts, human umbilical vein endothelial cells, human
microvascular endothelial cells, human epidermal melanocytes)
as well as the two cancer lines (HeLa and MCF-7) were harvested
by trypsinization, neutralized with trypsin inhibitor (primary cells
only), collected by centrifugation, decanted, and frozen on dry-
ice/ ethanol. Frozen pellets were transferred to a 280uC cryo-
freezer for storage. After eight months of storage, RNA was
isolated using Quiagen RNeasy kits (Quiagen, Valencia, CA).
Microfluidic Polymerase Chain Reaction
We used a BioMark
TM real-time PCR system (Fluidigm, San
Francisco, CA, USA) in conjunction with a BioMark 48.48
Dynamic Array, which has high throughput capacity due to its
integrated fluidic circuit feature [47]. First-strand cDNA was
prepared using SuperScript III First-Strand Synthesis SuperMix
for qPCR according to the manufacturer’s recommendations (Life
Technologies). Prior to analysis, cDNA from each sample was pre-
amplified using a 0.26 mixture of 25 Universal Probe Library
gene expression assays (Roche Applied Science, Indianapolis, IN)
and TaqManH PreAmp Master Mix (Life Technologies). cDNA
(1.25 ml) was amplified in a reaction (5 ml) for 14 cycles according
to the manufacturer’s recommendations. At the end of thermal
cycling, the reactions were diluted 1:5 in low EDTA TE (10 mM
Tris-HCl, pH 8.0; 0.1 mM EDTA, pH 8.0). Samples were
prepared for loading into the dynamic array by mixing TaqManH
Universal Master Mix (2.5 ml, Life Technologies), DA Sample
Loading Reagent (0.25 ml, PN 85000735; Fluidigm) and pre-
amplified cDNA (2.25 ml). The 48.48 Dynamic Array (PN BMK-
M-48.48; Fluidigm) was primed according to the manufacturer’s
recommendations. Samples (5 ml) were loaded into separate
sample inlets on the Dynamic Array. Gene expression assays
(Roche Applied Science) prepared as 206solutions were diluted to
106 using the DA Assay Loading Reagent (PN 85000735;
Fluidigm) and aliquots (5 ml) were loaded into separate reagent
inlets on the Dynamic Array. Each assay was run as technical
triplicates or quadruplicates, and loading positions across the array
were randomized. The dynamic array was placed on a
Nanoflex
TM 4-IFC Controller (Fluidigm) for loading and mixing.
After loading, the dynamic array was placed on the BioMark
TM
real-time PCR system for thermal cycling and real-time imaging of
the reactions. Thermal cycling conditions were: 50uC for 2 min
with AmpErase UNG (Life Technologies), 95uC for 10 min hot
start, and 40 cycles of 95uC for 15 s and 60uC for 1 min. Ct values
were determined using BioMark real-time PCR analysis software.
All other calculations, including reference gene stability, were
performed using Microsoft Excel (Microsoft, Redmond, WA).
We used the Universal Probe Library (Roche Applied Science,
Indianapolis, IN) set of sequence-specific probes and relied on the
Universal Probe Library assay design tool (www.roche-applied-
science.com) to choose primer sequences and the appropriate
fluorescent sequence-specific probe. All primers were purchased
from Sigma (St Louis, MO). For the list of all primer and probe
sequences used in this study, see Table S1.
Data processing
Ct values were determined from the 47 samples based upon the
mean of the Cts from technical replicates of assays used to detect
15 different putative reference genes. Next, the set of 47 Ct values
was converted to relative quantity for each of the 15 gene assays.
Calculations were performed as described by Vandesompele et al.
[8]. Briefly, a new array Ajk was calculated as the log2-transformed
expression ratios aij/aik for each combination of two control genes j
and k (i=1tom elements, m=47 for this study, equation 1). The
pairwise variation Vjk was calculated as the standard deviation of
the Ajk elements (equation 2). The stability of the control gene j (Mj)
was defined as the arithmetic mean of all pairwise variations Vjk
(equation 3).
Vj,k[ 1,n ½  and j=k ðÞ :
Ajk~ log2
a1j
a1k
  
,log2
a2j
a2k
  
,:::,log2
amj
amk
     
~ log2
aij
aik
     
i~1?m
ð1Þ
Vjk~st:dev Ajk
  
ð2Þ
Mj~
P n
k~1
Vjk
n{1
ð3Þ
The 15 reference genes were ranked in order of their stability M:
The reference gene having the lowest gene stability (highest value of
M, and in this case B2M) was eliminated from a new data set having
14 control genes, and new values of Ajk, Vjk,a n dMj were calculated
for the new data set. This process was repeated iteratively until only
two genes were remaining of the initial 15: PPIA and PGK1. The
geometric mean of these two genes was used to normalize the
expression of all other genes for each of the subsequent six dynamic
arrays where expression levels of query genes were assayed.
Clustering Analysis
Gene expression data were analyzed using the clustering
analysis software Cluster (Stanford) based on a clustering
algorithm described previously [48]. The similarity metric was
absolute correlation (centered) using the average linkage clustering
method. The clustered data was displayed as a heat map using
Java TreeView [49].
Supporting Information
Figure S1 Karyotypic analysis of hESC lines BG01 and
TE06.
(TIF)
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